Encelimab
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) [1].
Product Specifications
CAS Number
2173096-82-5
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/encelimab.html
Purity
95.25
Solubility
10 mM in DMSO
Smiles
[Encelimab]
Molecular Weight
(144.58 kDa)
References & Citations
[1]Perez-Santos M, et al. Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opin Drug Discov. 2022 Dec;17 (12) :1341-1355.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC432740 20 µg
SCP3 (SYCP3) (NM_001177949) Human Over-expression Lysate
Sign In for Pricing
View Details 
LC421111 20 µg
MAGEA9 (MAGEA9B) (NM_001080790) Human Over-expression Lysate
Sign In for Pricing
View Details